{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:44:39Z","timestamp":1792399479927,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijcard.2025.134042","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:57:23Z","timestamp":1764003443000},"page":"134042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes"],"prefix":"10.1016","volume":"445","author":[{"given":"Omar","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Nhat","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam","family":"Elbenawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayurkumar D.","family":"Bhakta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A.","family":"Sell-Dottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. David","family":"Fortuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeer","family":"Al-Kindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcard.2025.134042_bb0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.ijcard.2025.134042_bb0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2025.134042_bb0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"15","key":"10.1016\/j.ijcard.2025.134042_bb0020","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2025.134042_bb0025","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2025.134042_bb0030","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijcard.2016.06.283","article-title":"No benefit of additional treatment with exenatide in patients with an acute myocardial infarction","volume":"220","author":"Roos","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2025.134042_bb0035","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.ijcard.2025.134042_bb0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/ehjcvp\/pvaa004","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction","volume":"7","author":"Trevisan","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.ijcard.2025.134042_bb0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12933-023-02118-6","article-title":"GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"23","author":"Marfella","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134042_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12933-024-02548-w","article-title":"Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study","volume":"24","author":"Madsen","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.ijcard.2025.134042_bb0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2025.134042_bb0060","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"issue":"4","key":"10.1016\/j.ijcard.2025.134042_bb0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10193","key":"10.1016\/j.ijcard.2025.134042_bb0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ijcard.2025.134042_bb0075","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134042_bb0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13098-025-01635-6","article-title":"Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Mousavi","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"issue":"3","key":"10.1016\/j.ijcard.2025.134042_bb0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.ijcard.2025.134042_bb0090","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2025.134042_bb0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-022-07360-w","article-title":"Effects of glucagon-like Peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and Meta-analysis of randomized-controlled trials","volume":"38","author":"Wong","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2025.134042_bb0100","doi-asserted-by":"crossref","first-page":"1293926","DOI":"10.3389\/fcdhc.2023.1293926","article-title":"The benefits of GLP1 receptors in cardiovascular diseases","volume":"4","author":"Ferhatbegovic","year":"2023","journal-title":"Front. Clin. Diabet. Healthc"},{"issue":"1","key":"10.1016\/j.ijcard.2025.134042_bb0105","first-page":"83","article-title":"Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction","volume":"11","author":"Scalia","year":"2025","journal-title":"Cardiooncology"},{"issue":"1","key":"10.1016\/j.ijcard.2025.134042_bb0110","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134042_bb0115","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12933-024-02479-6","article-title":"Short- and long-term mortality in patients with type 2 diabetes after myocardial infarction- a nationwide registry study","volume":"23","author":"Kerola","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.ijcard.2025.134042_bb0120","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/dom.12827","article-title":"Long-term mortality after acute myocardial infarction among individuals with and without diabetes: a systematic review and meta-analysis of studies in the post-reperfusion era","volume":"19","author":"Gholap","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"Supplement_1","key":"10.1016\/j.ijcard.2025.134042_bb0125","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/dc24-SREV","article-title":"Summary of revisions: standards of Care in Diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice, C","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2025.134042_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732501085X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732501085X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:16:13Z","timestamp":1792397773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752732501085X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"alternative-id":["S016752732501085X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.134042","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.134042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"134042"}}